ROYALTY PHARMA PLC- CL A (RPRX) Forecast, Price Target & Analyst Ratings

NASDAQ:RPRX • GB00BMVP7Y09

Current stock price

50 USD
+1.52 (+3.14%)
At close:
49.8658 USD
-0.13 (-0.27%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ROYALTY PHARMA PLC- CL A (RPRX).

Forecast Snapshot

Consensus Price Target

Price Target
$53.03
+ 6.05% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
$1.23
Revenue Estimate
1.463B
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
83.75%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$53.03
Upside
+ 6.05%
From current price of $50.00 to mean target of $53.03, Based on 16 analyst forecasts
Low
$46.46
Median
$52.02
High
$64.05

Price Target Revisions

1 Month
1.22%
3 Months
14.43%

Price Target Summary

16 Wall Street analysts provided a forecast for the next 12 months for RPRX. The average price target is 53.03 USD. This implies a price increase of 6.05% is expected in the next year compared to the current price of 50.
The average price target has been revised upward by 14.43% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

RPRX Current Analyst RatingRPRX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

RPRX Historical Analyst RatingsRPRX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
83.75%
RPRX was analyzed by 16 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about RPRX.
In the previous month the buy percentage consensus was at a similar level.
RPRX was analyzed by 16 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-10Morgan StanleyMaintains Overweight -> Overweight
2026-01-27CitigroupMaintains Buy -> Buy
2025-12-11TD CowenMaintains Buy -> Buy
2025-10-10Morgan StanleyMaintains Overweight -> Overweight
2025-09-30Goldman SachsInitiate Buy
2025-07-22CitigroupMaintains Buy -> Buy
2025-07-10Morgan StanleyMaintains Overweight -> Overweight
2024-10-25CitigroupMaintains Buy -> Buy
2024-08-14Goldman SachsMaintains Buy -> Buy
2024-07-11Morgan StanleyMaintains Overweight -> Overweight
2024-06-03UBSDowngrade Buy -> Neutral
2024-04-12B of A SecuritiesMaintains Buy -> Buy
2024-02-20JP MorganMaintains Overweight -> Overweight
2024-02-20Goldman SachsMaintains Buy -> Buy
2023-11-09Morgan StanleyMaintains Overweight -> Overweight
2023-10-11Morgan StanleyMaintains Overweight -> Overweight
2023-08-09Morgan StanleyMaintains Overweight -> Overweight
2023-07-11Morgan StanleyReiterate Overweight -> Overweight
2023-05-10Morgan StanleyMaintains Overweight
2023-04-10Morgan StanleyMaintains Overweight
2023-02-16UBSMaintains Buy
2022-12-06Morgan StanleyMaintains Overweight
2022-11-09Morgan StanleyMaintains Overweight
2022-10-18JP MorganMaintains Overweight
2022-08-08Morgan StanleyMaintains Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
$1.23
Revenue Estimate
1.463B
Revenue Q2Q
74.37%
EPS Q2Q
89.88%
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
93.91%
EPS (1 Month)
0.00%
EPS (3 Months)
5.22%

Next Earnings Summary

RPRX is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is 1.23 USD and the consensus revenue estimate is 1.46B USD.
The next earnings revenue estimate has been revised upward by 93.91% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
RPRX revenue by date.RPRX revenue by date.
2.355B
5.25%		2.264B
-3.86%		2.378B
5.06%		3.289B
38.30%		3.447B
4.80%		3.757B
8.99%		4.678B
24.51%		5.093B
8.87%		5.342B
4.89%		5.662B
5.99%		5.832B
3.00%
EBITDA
YoY % growth
RPRX ebitda by date.RPRX ebitda by date.
N/A
7.26%		N/A
-6.92%		N/A
6.89%		3.164B
13.94%		3.384B
6.95%		3.809B
12.56%		4.313B
13.23%		4.712B
9.25%		4.974B
5.56%		5.326B
7.08%		5.489B
3.06%
EBIT
YoY % growth
RPRX ebit by date.RPRX ebit by date.
1.492B
61.68%		1.292B
-13.38%		1.56B
20.66%		3.005B
92.69%		3.05B
1.50%		3.067B
0.56%		2.5B
-18.49%		2.797B
11.88%		2.882B
3.04%		3.035B
5.31%		3.127B
3.03%
Operating Margin
RPRX operating margin by date.RPRX operating margin by date.
63.37%57.10%65.58%91.37%88.48%81.63%53.44%54.92%53.95%53.60%53.62%
EPS
YoY % growth
RPRX eps by date.RPRX eps by date.
4.38
19.35%		4.10
-6.39%		4.43
8.05%		5.17
16.65%		5.54
7.15%		6.20
12.06%		7.18
15.73%		7.86
9.52%		8.25
4.93%		8.76
6.18%		N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		1.23
89.88%		1.31
14.53%		1.19
1.71%		1.60
8.94%		1.35
9.09%		1.52
16.41%		1.34
12.29%		1.76
10.19%
Revenue
Q2Q % growth		1.463B
74.37%		717.63M
-1.29%		831.39M
2.14%		934.72M
50.28%		994.71M
-32.01%		883.77M
23.15%		977.04M
17.52%		1.01B
8.05%
EBITDA
Q2Q % growth		1.484B
106.82%		665.76M
5.66%		786.58M
10.83%		965.94M
30.94%		N/AN/AN/AN/A
EBIT
Q2Q % growth		1.516B
183.80%		656.38M
212.86%		755.34M
76.83%		831.34M
114.05%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

RPRX Yearly Revenue VS EstimatesRPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B 5B
RPRX Yearly EPS VS EstimatesRPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
11.89%
EPS Next 5 Year
12.16%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
5.93%
Revenue Next 5 Year
10.01%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
10.82%
EBIT Next 5 Year
10.98%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ROYALTY PHARMA PLC- CL A / RPRX Forecast FAQ

What do analysts expect the price target to be for ROYALTY PHARMA PLC- CL A (RPRX)?

16 analysts have analysed RPRX and the average price target is 53.03 USD. This implies a price increase of 6.05% is expected in the next year compared to the current price of 50.

What is the next earnings date for RPRX stock?

ROYALTY PHARMA PLC- CL A (RPRX) will report earnings on 2026-05-07.

What are the consensus estimates for RPRX stock next earnings?

The consensus EPS estimate for the next earnings of ROYALTY PHARMA PLC- CL A (RPRX) is 1.23 USD and the consensus revenue estimate is 1.46B USD.

What is the consensus rating for RPRX stock?

The consensus rating for ROYALTY PHARMA PLC- CL A (RPRX) is 83.75 / 100 . This indicates that analysts generally have a positive outlook on the stock.